Upregulation of intestinal mucosal mast cells expressing VPAC1 in close proximity to vasoactive intestinal polypeptide in inflammatory bowel disease and murine colitis

@article{CasadoBedmar2019UpregulationOI,
  title={Upregulation of intestinal mucosal mast cells expressing VPAC1 in close proximity to vasoactive intestinal polypeptide in inflammatory bowel disease and murine colitis},
  author={Maite Casado-Bedmar and St{\'e}phanie Heil and P{\"a}r Myrelid and Johan D S{\"o}derholm and {\AA}sa V. Keita},
  journal={Neurogastroenterology \& Motility},
  year={2019},
  volume={31}
}
Mast cells (MCs) and vasoactive intestinal polypeptide (VIP) have been proposed as regulators of the intestinal barrier and inflammation. Our aim was to map the distribution in inflammatory bowel disease (IBD) and murine colitis. 

Altered interaction between enteric glial cells and mast cells in the colon of women with irritable bowel syndrome

TLDR
Enteric glial cells and mast cells are intimately associated with gastrointestinal physiological functions and interaction in irritable bowel syndrome (IBS), a gut‐brain disorder linked to increased intestinal permeability, and MC is investigated.

Research advances of vasoactive intestinal peptide in the pathogenesis of ulcerative colitis by regulating interleukin-10 expression in regulatory B cells

TLDR
It is believed that Bregs can provide a novel strategy for the clinical treatment of UC with further clarity on the mechanism of the regulation of IL-10 expression by VIP in B Regs in colitis patients.

Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system

TLDR
The impact of VIP on gastrointestinal function and diseases based on recent findings is discussed, also providing insight into its possible therapeutic application to diabetes, autoimmune diseases and cancer.

Recent advances in vasoactive intestinal peptide physiology

TLDR
The impact of VIP on gastrointestinal function and diseases based on recent findings is discussed, also providing insight into its possible therapeutic application to diabetes, autoimmune diseases and cancer.

Intestinal Mucosal Mast Cells: Key Modulators of Barrier Function and Homeostasis

TLDR
The role played by mast cells in control of the intestinal mucosal barrier and their contribution to digestive diseases are described.

Cellular and Molecular Therapeutic Targets in Inflammatory Bowel Disease—Focusing on Intestinal Barrier Function

TLDR
This review will focus on the main cells and molecular mechanisms in IBD and how these can be targeted in order to improve intestinal barrier function and reduce inflammation.

Increased Colonic Epithelial Permeability and Mucosal Eosinophilia in Ulcerative Colitis in Remission Compared With Irritable Bowel Syndrome and Health

TLDR
A more permeable intestinal epithelium in inactive UC and IBS compared with HCs is indicated, suggesting both eosinophil numbers and activation state might be involved in the increased barrier function seen in UC patients in remission.

Mast Cells Modulate the Immune Response and Redox Status of the Gastrointestinal Tract in Induced Venom Pathogenesis.

TLDR
Results indicate that MCs might be involved in gastric modulation and intestinal inflammation through c-kit signaling following sub-cutaneous Aah venom injection.

Critical roles of G protein-coupled receptors in regulating intestinal homeostasis and inflammatory bowel disease.

TLDR
An overview of the essential physiological functions and signaling pathways of GPCRs and their roles in mucosal immunity and IBD regulation is provided.

Resveratrol Treatment Prevents Increase of Mast Cells in Both Murine OVA Enteritis and IL-10−/− Colitis

TLDR
Treatment with resveratrol prevented the increase in mast cells in both allergic enteritis and chronic colitis in duodenum as well as in colon and indicates that resver atrol may be considered as an anti-allergic and anti-inflammatory plant-derived component for the prevention or treatment of mast cell-associated disorders of the gastrointestinal tract.

References

SHOWING 1-10 OF 58 REFERENCES

Vasoactive intestinal polypeptide regulates barrier function via mast cells in human intestinal follicle‐associated epithelium and during stress in rats

TLDR
The aim was to elucidate the role of VIP in follicle‐associated epithelium (FAE) and villus epithelial permeability following stress in rats and on human intestinal barrier function.

Modulation of VIPergic phenotype of enteric neurons by colonic biopsy supernatants from patients with inflammatory bowel diseases: Involvement of IL‐6 in Crohn's disease

  • F. SouffletM. Biraud M. Neunlist
  • Biology, Medicine
    Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2018
TLDR
This work aimed to investigate the modulation of VIP expression in colonic biopsies of IBD patient, the ability of soluble factors fromBiopsies to reproduce in vitro these modulations and identify soluble factors responsible.

Vasoactive Intestinal Polypeptide and Mast Cells Regulate Increased Passage of Colonic Bacteria in Patients With Irritable Bowel Syndrome.

TLDR
It is found that colonic epithelium tissues from patients with IBS have increased translocation of commensal and pathogenic live bacteria compared with controls, and the mechanisms of increased translocated include MCs and VIP.

Vasoactive intestinal peptide ameliorates intestinal barrier disruption associated with Citrobacter rodentium-induced colitis.

  • V. ConlinX. Wu K. Jacobson
  • Biology, Medicine
    American journal of physiology. Gastrointestinal and liver physiology
  • 2009
TLDR
The results indicate that VIP protects the colonic epithelial barrier by minimizing bacterial-induced redistribution of tight junction proteins in part through actions on MLCK and MLC phosphorylation.

Vasoactive intestinal peptide impairs leucocyte migration but fails to modify experimental murine colitis

TLDR
Investigation of the VIP effects in a murine model of intestinal inflammation shows that, despite an ability to inhibit chemokine‐induced chemotaxis of mononuclear cells, VIP was unable to modulate TNBS‐induced colitis, suggesting that VIP is unlikely to provide a useful model for novel anti‐IBD therapy.

Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease.

TLDR
It is concluded that VIP-IR and SP-IR are distributed widely in the mucosa, submucosa, and in the circular muscle in normal colon, whereas VIP-ir is decreased in UC and CD, whereas SP- IR is increased in both, but more so in CD.

Recent advances in vasoactive intestinal peptide physiology and pathophysiology: focus on the gastrointestinal system

TLDR
The impact of VIP on gastrointestinal function and diseases based on recent findings is discussed, also providing insight into its possible therapeutic application to diabetes, autoimmune diseases and cancer.

Colonic vasoactive intestinal polypeptide (VIP) in ulcerative colitis--a radioimmunoassay and immunohistochemical study.

TLDR
The study shows clearly the heterogeneity in the response of VIP plasma level as well as rectum concentration and distribution in UC patients at different stages of the active disease.

Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease.

TLDR
The data suggest that VIP has beneficial prophylactic and therapeutic effects in TNBS-induced colitis and is a promising candidate to test for potential benefits in Crohn's disease.
...